Find comprehensive information on Plasma Cell Myeloma diagnosis, including ICD-10 codes, clinical documentation requirements, diagnostic criteria, and staging. Learn about relevant healthcare guidelines, treatment protocols, and medical coding best practices for accurate reporting of Plasma Cell Myeloma. This resource provides valuable insights for healthcare professionals, medical coders, and patients seeking information on this specific diagnosis.
Also known as
Multiple myeloma and plasma cell neoplasms
Malignant neoplasms of plasma cells, including multiple myeloma.
Malignant immunoproliferative diseases
Cancers of the immune system, some related to plasma cell disorders.
Secondary malignant neoplasm of bone and bone marrow
Cancer that has spread to bone, sometimes relevant in advanced myeloma.
Aplastic and other anemias
Anemia may be a complication or symptom of plasma cell myeloma.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the plasma cell myeloma active?
When to use each related code
| Description |
|---|
| Plasma cell myeloma |
| MGUS |
| Smoldering myeloma |
Insufficient documentation to differentiate myeloma type (e.g., IgG, IgA, light chain) impacting accurate coding and reimbursement.
Missing or unclear documentation of disease stage (ISS, R-ISS) affecting risk stratification and proper code assignment (e.g., C90.00-C90.09).
Misdiagnosis or inadequate documentation differentiating MGUS (monoclonal gammopathy of undetermined significance) from active myeloma, leading to coding errors.
Patient presents with symptoms suggestive of plasma cell myeloma (PCM), including bone pain, fatigue, anemia, and recurrent infections. Laboratory findings reveal elevated serum calcium, renal insufficiency indicated by elevated creatinine, and evidence of monoclonal protein (M protein) on serum protein electrophoresis (SPEP) and urine protein electrophoresis (UPEP). A bone marrow biopsy confirms the diagnosis, demonstrating an abnormal plasma cell proliferation exceeding 10% and presence of clonal plasma cells. The patient meets the International Myeloma Working Group (IMWG) diagnostic criteria for symptomatic myeloma. Differential diagnoses considered included monoclonal gammopathy of undetermined significance (MGUS), smoldering myeloma, and Waldenstrom macroglobulinemia. Further diagnostic workup includes skeletal surveys to assess for lytic lesions, serum free light chain assay, and beta-2 microglobulin levels for prognostic stratification, and cytogenetic analysis to identify high-risk chromosomal abnormalities. Treatment plan will be discussed with the patient and may include options such as chemotherapy, targeted therapy (e.g., proteasome inhibitors, immunomodulatory drugs), stem cell transplantation, and supportive care including bisphosphonates for bone health and management of renal complications. Follow-up appointments are scheduled to monitor treatment response, disease progression, and potential adverse effects. ICD-10 code C90.00, Multiple myeloma not otherwise specified, is assigned.